virion was founded by Andrew Luber, Bernie Rudnick in 2018.

Who are virion's investors?

virion's investors include Keiretsu Forum, Robin Hood Ventures.

How much funding has virion raised?

virion has disclosed $10.9M raised across 2 rounds.

Where is virion headquartered?

virion is headquartered in Newark, US.

virion

Newark, US · Founded 2018 · 2 known investors

Find your way into virion

Each arrow is one introduction. Sign up to fill in the first one.

111 people can intro you to Andrew

Ask David Neafus to introduce you to Andrew Luber

You →David · together at virion →Andrew

30 people can intro you to Bernie

Ask Jamie Chen to introduce you to Bernie Rudnick

You →Jamie · together at CapGenic Advisors, LLC →Bernie

Your email: who you already know at virion, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the virion team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Virion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.

Biotech Healthtech

Founders & leadership

virion was founded in 2018 by Andrew Luber and Bernie Rudnick.

Andrew Luber Co-founder · President & CEOAndrew Luber is a clinical pharmacist with over 25 years of experience in antiviral and infectious disease research, including investigator roles in more than 40 Phase I-III clinical trials and expertise in HIV and hepatitis C pharmacology.

Bernie Rudnick Co-founder · Retired CEO, Virion Therapeutics, LLCBernie Rudnick held C-level positions at biotechnology companies Immunomic Therapeutics and Atrin Pharmaceuticals before co-founding Virion Therapeutics with Dr. Andy Luber, Dr. Hildegund Ertl, and the Wistar Institute. He has extensive experience in executive management, mergers and acquisitions, and capital formation across biotechnology companies ranging from startups to large enterprises.

Bernard RudnickNamed on SEC filing

Investors · 2

Keiretsu Forumlisted by Keiretsu ForumSan Francisco East Bay · $250K – $2M

How we know: Keiretsu Forum's portfolio page · Not right? Tell us

Robin Hood Ventureslisted by Robin Hood VenturesPhiladelphia · $250K – $1Mvia Pitou Devgon · inferred

How we know: Robin Hood Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$10.9M disclosed across 2 rounds · 2018–2019

▶$5.7MraisedOct 2021 · 49 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Andrew LuberExecutive Officer, Director
Bernard RudnickExecutive Officer, Director

Offering amount: $6M
Amount sold: $5.7M
Minimum investment: $25K
First sale: Oct 2019
Incorporated: Limited Liability Company, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.2MraisedNov 2018 · 80 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Bernard RudnickExecutive Officer, Director
Andrew LuberExecutive Officer, Director

Offering amount: $5.5M
Amount sold: $5.2M
Minimum investment: $25K
First sale: Jun 2018
Incorporated: Limited Liability Company, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Aurion BiotechAurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.

Vividion TherapeuticsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.

Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

VivoryonVivoryon is a biotech company focused on developing therapeutics, with a leadership team experienced in pharmaceutical development, clinical research, and life sciences business operations.

VeratxVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.

Companies working in the same space as virion.

Frequently asked questions

What does virion do?: Virion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.
Who founded virion?: virion was founded by Andrew Luber, Bernie Rudnick in 2018.
Who are virion's investors?: virion's investors include Keiretsu Forum, Robin Hood Ventures.
How much funding has virion raised?: virion has disclosed $10.9M raised across 2 rounds.
Where is virion headquartered?: virion is headquartered in Newark, US.